← all projects
ARIA Opportunity Space: Scalable Neural Interfaces
AI for Biomaterials Design
We are building an automated platform that uses artificial intelligence to design and optimize nanoparticles for medical applications such as enabling brain-specific delivery. Our system combines robotic laboratory equipment with AI algorithms that learn from experimental results to rapidly discover optimal nanoparticle recipes, replacing the current time-consuming trial-and-error approach. The platform will process hundreds of different nanoparticle formulations simultaneously, using real-time measurements of particle properties to guide the AI in selecting the most promising combinations. By automating and accelerating nanoparticle development, we aim to reduce optimization time from months to days while creating better-performing particles for medical applications such as neurological diseases, potentially accelerating the development of new treatments and therapies.
Dame Molly Stevens
Professor, Bionanoscience
Dame Molly Stevens leads The Stevens Group, innovating biomaterials design for biosensing and therapeutics. She is also a serial entrepreneur with numerous patents filed and 4 spin-out companies based on her research.